Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (691-700 of 1,058) with videos related to

Pageof 106
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agentsRosa Lapalombella, Xiaobin Zhao, Georgia Triantafillou, et al.
Blood|July 19, 2018
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLLSean D Reiff, Elizabeth M Muhowski, Daphne Guinn, et al.
Leukemia Research|August 2, 2014
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemiaKami Maddocks, Amy S Ruppert, Rebekah Browning, et al.
The Lancet. Haematology|November 4, 2021
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 studyToby A Eyre, Anna Schuh, William G Wierda, et al.
Journal of Hematology & Oncology|October 20, 2020
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemiaLindsey T Brinton, Pu Zhang, Katie Williams, et al.
Blood|January 10, 2008
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitroAruna Gowda, Julie Roda, Syed-Rehan A Hussain, et al.
Plos One|November 13, 2010
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol dispositionWenjun Ni, Jia Ji, Zunyan Dai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignanciesMehdi Hamadani, William Blum, Gary Phillips, et al.
Blood|March 12, 2014
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)Brad S Kahl, Stephen E Spurgeon, Richard R Furman, et al.
Leukemia|October 8, 2015
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemiaK A Rogers, A S Ruppert, A Bingman, et al.
Pageof 106

Showing results (691-700 of 1,058) with videos related to

Sort By:
Pageof 106
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agentsRosa Lapalombella, Xiaobin Zhao, Georgia Triantafillou, et al.
Blood|July 19, 2018
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLLSean D Reiff, Elizabeth M Muhowski, Daphne Guinn, et al.
Leukemia Research|August 2, 2014
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemiaKami Maddocks, Amy S Ruppert, Rebekah Browning, et al.
The Lancet. Haematology|November 4, 2021
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 studyToby A Eyre, Anna Schuh, William G Wierda, et al.
Journal of Hematology & Oncology|October 20, 2020
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemiaLindsey T Brinton, Pu Zhang, Katie Williams, et al.
Blood|January 10, 2008
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitroAruna Gowda, Julie Roda, Syed-Rehan A Hussain, et al.
Plos One|November 13, 2010
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol dispositionWenjun Ni, Jia Ji, Zunyan Dai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignanciesMehdi Hamadani, William Blum, Gary Phillips, et al.
Blood|March 12, 2014
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)Brad S Kahl, Stephen E Spurgeon, Richard R Furman, et al.
Leukemia|October 8, 2015
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemiaK A Rogers, A S Ruppert, A Bingman, et al.
Pageof 106